In preclinical breast cancer models, transplantation of engineered TIE2-expressing macrophages that express IFNα reprograms the TME, inducing greater DC activation and CD8+ T cell cytotoxicity against tumor cells [71]. The gene discussed is IFNA1; the disease is breast cancer.